NRG GY018

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Gynecologic

Status:

Upcoming - Pending IRB Review

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer

NCT#03914612